SANOFI-AVENTIS (EPA:SAN)

BRIEF

published on 06/03/2024 at 22:20, 10 months 11 days ago

Phase III study: Sarclisa improves progression-free survival of patients with multiple myeloma

Multiple Myeloma Sarclisa ASCO Phase III Study Progression-free Survival
PRESS RELEASE

published on 06/03/2024 at 22:15, 10 months 11 days ago

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Sarclisa in combo with VRd significantly enhances progression-free survival in newly diagnosed transplant-ineligible multiple myeloma in phase 3 study at ASCO. Full data published in NEJM

Multiple Myeloma Phase 3 Sarclisa Progression-free Survival VRd
BRIEF

published on 05/31/2024 at 12:05, 10 months 14 days ago

Sanofi Launches 2024 Global Employee Stock Purchase Plan

Financial Investment Sanofi Employee Stock Purchase Plan Action 2024 Global Participation
PRESS RELEASE

published on 05/31/2024 at 12:00, 10 months 14 days ago

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan, Action 2024, offering discounted shares to 80,000 employees in 56 countries. CEO Paul Hudson affirms commitment to employee participation and company growth

Company Growth Sanofi Employee Stock Purchase Plan Action 2024 Employee Shareholders
BRIEF

published on 05/31/2024 at 07:10, 10 months 14 days ago

CHMP recommends approval of Dupixent in the EU for the treatment of patients with COPD

Sanofi COPD Dupixent CHMP Supply
PRESS RELEASE

published on 05/31/2024 at 07:05, 10 months 14 days ago

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU

Dupixent CHMP EU Approval COPD Treatment Type 2 Inflammation
BRIEF

published on 05/30/2024 at 15:06, 10 months 15 days ago

Sanofi Completes Acquisition of Inhibrx, Inc.

Acquisition Sanofi Rare Diseases Inhibrx SAR447537
PRESS RELEASE

published on 05/30/2024 at 15:01, 10 months 15 days ago

Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB

Acquisition Nasdaq Sanofi Inhibrx SAR447537
BRIEF

published on 05/27/2024 at 07:05, 10 months 18 days ago

FDA Grants Priority Review to Sarclisa for Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa Chemotherapy
BRIEF

published on 05/21/2024 at 07:35, 10 months 24 days ago

Sanofi, Formation Bio, and OpenAI Announce AI Collaboration

Collaboration AI Drug Development Sanofi OpenAI Formation Bio

Published on 04/14/2025 at 22:30, 13 minutes ago

Bausch Health Announces Adoption of Shareholder Rights Plan
Published on 04/14/2025 at 22:15, 28 minutes ago

Kingstone Announces Renewal Rights Transaction to Grow Homeowners Insurance Business in Downstate New York
Published on 04/14/2025 at 18:00, 4 hours 43 minutes ago

IEH Corporation to Present at the Planet MicroCap Showcase
Published on 04/14/2025 at 15:20, 7 hours 23 minutes ago

MicroVision Attains TISAX Assessment, An Important Achievement in Global Auto Industry
Published on 04/14/2025 at 15:00, 7 hours 43 minutes ago

Wi2Wi Corporation Announces Full Year 2024 Financial Results

View all ACCESSWIRE

Published on 04/14/2025 at 20:38, 2 hours 4 minutes ago

Share Buyback
Published on 04/14/2025 at 20:10, 2 hours 33 minutes ago

Morocco sets the stage for Africa’s digital future ahead of continental launchpad event for innovation, Artificial Intelligence (AI) and digital leadership in Marrakech
Published on 04/14/2025 at 19:02, 3 hours 40 minutes ago

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2025: EBIT below prior year – forecast confirmed due to good order development
Published on 04/14/2025 at 18:44, 3 hours 58 minutes ago

Rack Centre’s LGS2 12MW Data Centre, gamechanger to revolutionise Nigeria’s Digital Landscape
Published on 04/14/2025 at 18:44, 3 hours 58 minutes ago

fox e-mobility AG: Implementation of the Capital Resolutions of the Annual General Meeting -Financial Calendar

View all EQS

Published on 04/14/2025 at 18:04, 4 hours 38 minutes ago

Disclosure of trading in own shares between April 7th and April 11th, 2025
Published on 04/14/2025 at 17:45, 4 hours 58 minutes ago

PR - Decision of the Board of Directors on April 13, 2025
Published on 04/14/2025 at 17:45, 4 hours 58 minutes ago

Weekly share buyback
Published on 04/14/2025 at 17:35, 5 hours 8 minutes ago

Disclosure of transactions in own shares from April 7 to April 11, 2025
Published on 04/14/2025 at 08:15, 14 hours 27 minutes ago

Aéroports de Paris SA - Filing of the 2024 Universal Registration Document

View all LES ECHOS COMFI WIRE

News